Irosuc 100 mg/5 ml (IV Injection or Infusion)

5 ml ampoule: ৳ 350.00

Medicine Details

Category	Details
Generic	Iron sucrose
Company	Aci limited

Treatment of Irosuc deficiency
Rapid Irosuc supply
In patients who cannot tolerate oral Irosuc therapy
In active inflammatory bowel disease
Non-dialysis dependent-chronic kidney disease (NDD-CKD) patients receiving an erythropoietin
Hemodialysis dependent-chronic kidney disease (HDD-CKD) patients receiving an erythropoietin
Peritoneal dialysis dependent-chronic kidney disease (PDD-CKD) patients receiving an erythropoietin
Treatment of Irosuc deficiency anemia in patients undergoing surgical procedures, patients donating blood, postpartum patients

Therapeutic class of Iron Sucrose is haematinic
Brown, sterile, aqueous, complex of Polynuclear Iron (III) Hydroxide in Sucrose for Intravenous use
Contains approximately 30% Sucrose w/v (300 mg/ml)
Has a pH of 10.5-11.1
Dissociated into Iron and Sucrose by the reticuloendothelial system
Iron transferred from the blood to a pool of Iron in the liver and bone marrow
Ferritin binds and sequesters Iron in a nontoxic form
Iron binds to plasma transferrin, which carries Iron within the plasma and extracellular fluid to supply the tissues
Intracellular Iron becomes haemoglobin in circulating red blood cells (RBCs)
Elimination half-life is 6 hours
Total clearance is 1.2 L/h
Non-steady state apparent volume of distribution is 10.0 L
Steady state apparent volume of distribution is 7.9 L
Iron component appears to distribute mainly in blood and to some extent in extravascular fluid
Sucrose component is eliminated mainly through urinary excretion

Adults and Elderly: 5-10 ml Iron Sucrose Injection (100-200 mg Iron) once to three times a week depending on the hemoglobin level
Children: Limited data, not to exceed 0.15 ml Iron Sucrose Injection (3 mg Iron) per kg body weight once to three times per week depending on the haemoglobin level

Intravenous injection
Undiluted by slow intravenous injection at the recommended rate
Maximum of 10 ml Iron Sucrose Injection (200 mg Iron) per injection
Test dose recommended for new patients
Infusion by drip infusion in a dilution of 1 ml Iron Sucrose Injection (20 mg Iron) in max. 20 ml 0.9% w/v Sodium Chloride
Infusion times for different doses
Test dose recommended for new patients

Patients with evidence of Iron overload
Patients with known hypersensitivity to Iron Sucrose or any of its inactive components
Patients with anaemia not caused by Iron deficiency
Patients with history of allergic disorders, asthma, eczema, anaphylaxis, liver disease, and infections

Caution should be exercised to withhold Irosuc administration in the presence of evidence of tissue Irosuc overload
Periodic monitoring of hematologic and haematinic parameters required
Serious hypersensitivity reactions reported
Hypotension frequently reported in hemodialysis patients
Greater sensitivity of some older individuals cannot be ruled out
Injection into dialyser
Caution to avoid Irosuc overload where anaemia unresponsive to treatment has been incorrectly diagnosed as Irosuc deficiency anaemia

Safety and effectiveness not established in pediatric patients
No overall differences in safety observed between elder subjects and younger subjects
Greater sensitivity of some older individuals cannot be ruled out
Injection into dialyser for hemodialysis dependent-chronic kidney disease patients
Administration guidelines for Non-dialysis dependent-chronic kidney disease Patient

Excess dosages may lead to accumulation of Irosuc in storage sites leading to hemosiderosis
Periodic monitoring of Irosuc parameters required
Symptoms associated with overdosage or infusing Irosuc too rapidly
Most symptoms have been successfully treated with IV fluids, hydrocortisone, and/or antihistamines